WO2019214196A1 - Spray-drying method for pogostemon cablin granular formulation - Google Patents

Spray-drying method for pogostemon cablin granular formulation Download PDF

Info

Publication number
WO2019214196A1
WO2019214196A1 PCT/CN2018/114811 CN2018114811W WO2019214196A1 WO 2019214196 A1 WO2019214196 A1 WO 2019214196A1 CN 2018114811 W CN2018114811 W CN 2018114811W WO 2019214196 A1 WO2019214196 A1 WO 2019214196A1
Authority
WO
WIPO (PCT)
Prior art keywords
spray drying
spray
patchouli
concentrated
drying method
Prior art date
Application number
PCT/CN2018/114811
Other languages
French (fr)
Chinese (zh)
Inventor
张保献
李艳英
李欣欣
Original Assignee
北京盈科瑞创新医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京盈科瑞创新医药股份有限公司 filed Critical 北京盈科瑞创新医药股份有限公司
Priority to KR1020207034397A priority Critical patent/KR102466375B1/en
Priority to JP2021510502A priority patent/JP7150142B2/en
Publication of WO2019214196A1 publication Critical patent/WO2019214196A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • the invention relates to the technical field of traditional Chinese medicine formula granule production, in particular to an improved spray-drying method of patchouli granules, belonging to the technical field of traditional Chinese medicine production.
  • the traditional Chinese medicine formula granules are prepared by extracting and concentrating the single-flavored traditional Chinese medicine decoction pieces for the clinical formula of Chinese medicine.
  • Formerly known as single-flavor Chinese medicine concentrated granules the name of the commodity and the folk name are also free of Chinese herbal medicine pieces, new pieces, refined pieces, beverage-type pieces, scientific Chinese medicine and so on.
  • the drying process is an important part in the preparation of Chinese medicine formula granules.
  • traditional Chinese medicine extracts such as vacuum drying, freeze drying, fluidized bed drying, spray drying and the like.
  • spray drying has the advantages of short drying time, large drying area and less damage of active ingredients, and is an ideal method for drying liquid semi-liquid materials of traditional Chinese medicine.
  • the Chinese herb patchouli is the dry aerial part of the Pogostemon cablin (Blanco) Benth. It has the effect of aromatizing turbidity, and stopping vomiting, and releasing the effect of relieving heat. It is mainly used for the treatment of wet turbidity, vomiting, phlegm, phlegm, dampness, fever, burnout, chest tightness, cold and dampness. Abdominal pain, vomiting and diarrhea, nasal headache.
  • the Chinese invention patent application (CN107397787A) discloses a preparation process of a patchouli fresh-squeezed spray-dried granules, which concentrates the pressed patchouli medicinal juice under reduced pressure at 40-80 ° C to obtain a relative density of 1.02 to 1.10. The concentrated liquid is then spray dried, and the air inlet temperature is set to 100 to 140 ° C, and the outlet temperature is set to 90 to 120 ° C, and spray drying is directly performed.
  • the object of the present invention is to overcome the deficiencies of the prior art, to provide a process which is simple for industrial production, can effectively prevent the sticking phenomenon in the spray drying process, and effectively improve the yield of the dry paste powder in the spray drying process of the traditional Chinese medicine extract. Patchouli Chinese Herbal Formula Granule Spray Drying Process.
  • the technical solution adopted by the present invention is:
  • a method for spray drying a patchouli Chinese medicine formula comprising the steps of: taking a concentrated patchouli extract, then adding 2% to 5% beta cyclodextrin, mixing, filtering, and advancing
  • the air temperature was 175 ° C to 180 ° C, and the air temperature was 90 ° C to 95 ° C under spray drying to collect the dry paste powder.
  • the concentrated extract has a relative density of from 1.02 to 1.10, preferably from 1.03 to 1.10 at 60 °C.
  • the concentrated extract has a relative density of 1.05 to 1.08 at 60 °C.
  • the extract is added with 3% to 4% of betacyclodextrin.
  • 3% beta-cyclodextrin is added.
  • the inlet air temperature during spray drying is 175 ° C, and the outlet air temperature is 95 ° C.
  • the spray drying method has a dry paste yield of 78.02% to 96.56%, preferably 78.02%, 81.09%, 81.15%, 84.57%, 95.44% or 96.56%.
  • the amount of beta-cyclodextrin added in the present application is calculated based on the weight of the concentrated patchouli extract.
  • the concentrated patchouli extract was taken to have a relative density of 1.05 (60 ° C), spray-dried at an inlet air temperature of 175 ° C, and an outlet air temperature of 95 ° C to collect dry paste powder.
  • the concentrated patchouli extract was obtained at a relative density of 1.05 (60 ° C), then added with 3% cyclodextrin, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
  • the concentrated patchouli extract was taken at a relative density of 1.05 (60 ° C), then 4% beta-cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet air temperature of 95 ° C. Spray dry and collect dry paste powder.
  • the concentrated patchouli extract was taken at a relative density of 1.03 (60 ° C), then 3% times cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
  • the concentrated patchouli extract was taken at a relative density of 1.01 (60 ° C), then 3% times cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet air temperature of 95 ° C. Spray dry and collect dry paste powder.
  • the concentrated patchouli extract was taken at a relative density of 1.11 (60 ° C), then 3% times cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
  • the concentrated patchouli extract was taken at a relative density of 1.05 (60 ° C), then 1.5% beta-cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A spray-drying method for Pogostemon cablin granular formulation, comprising the following steps: taking a concentrated Pogostemon cablin extractum, adding 2% to 5% of beta-cyclodextrin, mixing uniformly, performing filtration, performing spray drying under conditions of an inlet air temperature of 175 °C to 180 °C and an outlet air temperature of 90 °C to 95 °C and collecting dry powders. The concentrated extractum has a relative density of 1.02 to 1.10 at 60 °C.

Description

一种广藿香配方颗粒喷雾干燥方法Patchouli formula particle spray drying method 技术领域Technical field
本发明涉及中药配方颗粒生产技术领域，具体涉及一种改善的广藿香配方颗粒喷雾干燥方法，属于中药生产技术领域。The invention relates to the technical field of traditional Chinese medicine formula granule production, in particular to an improved spray-drying method of patchouli granules, belonging to the technical field of traditional Chinese medicine production.
背景技术Background technique
中药配方颗粒是由单味中药饮片经提取浓缩制成的、供中医临床配方用的颗粒。国内以前称单味中药浓缩颗粒剂，商品名及民间称呼还有免煎中药饮片、新饮片、精制饮片、饮料型饮片、科学中药等。The traditional Chinese medicine formula granules are prepared by extracting and concentrating the single-flavored traditional Chinese medicine decoction pieces for the clinical formula of Chinese medicine. Formerly known as single-flavor Chinese medicine concentrated granules, the name of the commodity and the folk name are also free of Chinese herbal medicine pieces, new pieces, refined pieces, beverage-type pieces, scientific Chinese medicine and so on.
干燥工艺是中药配方颗粒制备中的一个重要环节，中药浸膏干燥的方法有很多种，如真空干燥、冷冻干燥、流化床干燥、喷雾干燥等。其中，喷雾干燥具有干燥时间短、干燥面积大、有效成分破坏少等优点，是用于中药液态半液态物料干燥的一种较为理想的方法。The drying process is an important part in the preparation of Chinese medicine formula granules. There are many methods for drying traditional Chinese medicine extracts, such as vacuum drying, freeze drying, fluidized bed drying, spray drying and the like. Among them, spray drying has the advantages of short drying time, large drying area and less damage of active ingredients, and is an ideal method for drying liquid semi-liquid materials of traditional Chinese medicine.
中药广藿香为唇形科植物广藿香Pogostemon cablin(Blanco)Benth.的干燥地上部分。具有芳香化浊，和中止呕，发表解暑的功效，主要用于治疗湿浊中阻，脘痞呕吐，暑湿表证，湿温初起，发热倦怠，胸闷不舒，寒湿闭暑，腹痛吐泻，鼻渊头痛。The Chinese herb patchouli is the dry aerial part of the Pogostemon cablin (Blanco) Benth. It has the effect of aromatizing turbidity, and stopping vomiting, and releasing the effect of relieving heat. It is mainly used for the treatment of wet turbidity, vomiting, phlegm, phlegm, dampness, fever, burnout, chest tightness, cold and dampness. Abdominal pain, vomiting and diarrhea, nasal headache.
广藿香作为中药配方颗粒使用已经是现有技术，但关于广藿香配方颗粒干燥技术的公开的内容较少。中国发明专利申请(CN107397787A)公开了一种广藿香鲜榨喷雾干燥颗粒饮片的制备工艺，其将压榨得到的广藿香药汁于40～80℃减压浓缩，得到相对密度为1.02～1.10的浓缩液，然后进行喷雾干燥，进风口温度设定为100～140℃,出风口温度设定为90～120℃条件下直接进行喷雾干燥。CN107397787A中公开的方法尽管简单易操作，但由于广藿香中含有各种醇、酮、糖苷等成分，会因为料液粘度较大，造成药液在在喷雾干燥过程中粘塔现象，不仅严重影响喷雾干燥效率，还会损失部分物料、降低干膏粉的收率。It has been a prior art to use patchouli as a Chinese medicine formula granule, but there is less disclosure about the patchouli granule drying technique. The Chinese invention patent application (CN107397787A) discloses a preparation process of a patchouli fresh-squeezed spray-dried granules, which concentrates the pressed patchouli medicinal juice under reduced pressure at 40-80 ° C to obtain a relative density of 1.02 to 1.10. The concentrated liquid is then spray dried, and the air inlet temperature is set to 100 to 140 ° C, and the outlet temperature is set to 90 to 120 ° C, and spray drying is directly performed. Although the method disclosed in CN107397787A is simple and easy to operate, since the patchouli contains various alcohols, ketones, glycosides and the like, the viscosity of the liquid is large, which causes the liquid to stick to the tower during the spray drying process, which is not only serious. Affecting spray drying efficiency, it will also lose some materials and reduce the yield of dry paste powder.
发明内容Summary of the invention
技术问题technical problem
本发明的目的在于克服现有技术的不足，提供一种工艺简单利于工业化生产、能够有效防止喷雾干燥过程中的粘壁现象、且有效提高中药浸膏在喷雾干燥过程中干膏粉收率的广藿香中药配方颗粒喷雾干燥工艺。The object of the present invention is to overcome the deficiencies of the prior art, to provide a process which is simple for industrial production, can effectively prevent the sticking phenomenon in the spray drying process, and effectively improve the yield of the dry paste powder in the spray drying process of the traditional Chinese medicine extract. Patchouli Chinese Herbal Formula Granule Spray Drying Process.
解决方案solution
为了解决上述技术问题，本发明所采用的技术方案是：In order to solve the above technical problems, the technical solution adopted by the present invention is:
一种广藿香中药配方颗粒喷雾干燥方法，所述方法包含如下步骤：取浓缩后的广藿香浸膏，然后加入2％～5％倍他环糊精，混匀，滤过，在进风温度175℃～180℃，出风温度90℃～95℃条件下进行喷雾干燥，收集干膏粉。A method for spray drying a patchouli Chinese medicine formula, the method comprising the steps of: taking a concentrated patchouli extract, then adding 2% to 5% beta cyclodextrin, mixing, filtering, and advancing The air temperature was 175 ° C to 180 ° C, and the air temperature was 90 ° C to 95 ° C under spray drying to collect the dry paste powder.
如上所述的喷雾干燥方法，作为一种优选方式，其中所述浓缩后的浸膏在60℃相对密度为1.02至1.10，优选为1.03至1.10。The spray drying method as described above, as a preferred mode, wherein the concentrated extract has a relative density of from 1.02 to 1.10, preferably from 1.03 to 1.10 at 60 °C.
如上所述的喷雾干燥方法，作为一种优选方式，其中所述浓缩后的浸膏在60℃相对密度为1.05至1.08。As the spray drying method as described above, as a preferred mode, the concentrated extract has a relative density of 1.05 to 1.08 at 60 °C.
如上所述的喷雾干燥方法，作为一种优选方式，其中浸膏加入3％～4％的倍他环糊精。优选加入3％的倍他环糊精。As the spray drying method as described above, as a preferred embodiment, the extract is added with 3% to 4% of betacyclodextrin. Preferably, 3% beta-cyclodextrin is added.
如上所述的喷雾干燥方法，作为一种优选方式，喷雾干燥中的进风温度为175℃，出风温度为95℃。As the spray drying method as described above, as a preferred mode, the inlet air temperature during spray drying is 175 ° C, and the outlet air temperature is 95 ° C.
如上所述的喷雾干燥方法，作为一种优选方式，其中所述干膏收率为78.02％～96.56％，优选为78.02％、81.09％、81.15％、84.57％、95.44％或96.56％。As a preferred embodiment, the spray drying method has a dry paste yield of 78.02% to 96.56%, preferably 78.02%, 81.09%, 81.15%, 84.57%, 95.44% or 96.56%.
作为常用的计量方式，本申请中倍他环糊精的加入量是以浓缩后的广藿香浸膏的重量为基准来计算的。As a commonly used metering method, the amount of beta-cyclodextrin added in the present application is calculated based on the weight of the concentrated patchouli extract.
发明人通过多年对中药配方颗粒喷雾干燥的研究，惊奇的发现，在制备广藿香配方颗粒时，只需加入少量倍它环糊精作为广藿香配方颗粒喷雾干燥的辅料，即可极大改善喷雾干燥过程中的粘塔现象，极大地提高广藿香配方颗粒喷雾干燥过程中的干膏收率。现有技术一般认为倍他环糊精作为常用的药用辅料，主要用于挥发油的包合，而较少作为喷雾干燥的辅料，少量文献报道其使用的用量也在5％以上，而辅料用量过多，不仅影响配方颗粒中主药的含量，增加病人服用量，还会造成工业化生产中的成本增大等不利效果。同时申请人还发现，广藿香浸膏的相对密度同样是影响喷雾干燥工艺及干膏收率的一大因素，相对密度过大或过小均会影响喷雾干燥情况及干膏收率，相对密度处于合适范围利于喷雾干燥过程中的工艺控制及干膏粉收率。After many years of research on the spray drying of traditional Chinese medicine formula particles, the inventors have surprisingly found that in the preparation of patchouli granules, it is only necessary to add a small amount of cyclodextrin as a spray-dried excipient for patchouli granules. Improve the sticking tower phenomenon during spray drying, and greatly improve the dry paste yield during the spray drying process of patchouli formula particles. The prior art generally considers beta-cyclodextrin as a commonly used pharmaceutical excipient, mainly used for the inclusion of volatile oils, and less as an auxiliary material for spray drying, and a small amount of literature reports that the amount used is also more than 5%, and the amount of auxiliary materials. Excessive, not only affects the content of the main drug in the formula granules, increases the dosage of the patient, but also causes an unfavorable effect such as an increase in cost in industrial production. At the same time, the applicant also found that the relative density of patchouli extract is also a major factor affecting the spray drying process and dry paste yield. If the relative density is too large or too small, it will affect the spray drying condition and dry cream yield. The density is in the proper range to facilitate process control and dry paste powder yield during spray drying.
具体实施方式detailed description
下面通过实施例对本发明做进一步详细说明，这些实施例仅用来说明本发明，并不限制本发明的范围。The invention is further illustrated by the following examples, which are intended to illustrate the invention and not to limit the scope of the invention.
实施例1Example 1
取浓缩后的广藿香浸膏，相对密度为1.05(60℃)，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was taken to have a relative density of 1.05 (60 ° C), spray-dried at an inlet air temperature of 175 ° C, and an outlet air temperature of 95 ° C to collect dry paste powder.
实施例2Example 2
取浓缩后的广藿香浸膏，相对密度为1.05(60℃)，然后加入2％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。Take the concentrated patchouli extract, the relative density is 1.05 (60 ° C), then add 2% beta cyclodextrin, mix, filter, at the inlet air temperature of 175 ° C, the outlet temperature of 95 ° C Spray dry and collect dry paste powder.
实施例3Example 3
取浓缩后的广藿香浸膏，相对密度为1.05(60℃)，然后加入3％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was obtained at a relative density of 1.05 (60 ° C), then added with 3% cyclodextrin, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
实施例4Example 4
取浓缩后的广藿香浸膏，相对密度为1.05(60℃)，然后加入4％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was taken at a relative density of 1.05 (60 ° C), then 4% beta-cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet air temperature of 95 ° C. Spray dry and collect dry paste powder.
实施例5Example 5
取浓缩后的广藿香浸膏，相对密度为1.03(60℃)，然后加入3％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was taken at a relative density of 1.03 (60 ° C), then 3% times cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
实施例6Example 6
取浓缩后的广藿香浸膏，相对密度为1.08(60℃)，然后加入3％倍他环 糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。Take the concentrated patchouli extract, the relative density is 1.08 (60 ° C), then add 3% times cyclodextrin, mix, filter, at the inlet air temperature of 175 ° C, the outlet temperature of 95 ° C Spray dry and collect dry paste powder.
实施例7Example 7
取浓缩后的广藿香浸膏，相对密度为1.10(60℃)，然后加入3％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。Take the concentrated patchouli extract, the relative density is 1.10 (60 ° C), then add 3% times cyclodextrin, mix, filter, at the inlet air temperature of 175 ° C, the outlet temperature of 95 ° C Spray dry and collect dry paste powder.
实施例8Example 8
取浓缩后的广藿香浸膏，相对密度为1.01(60℃)，然后加入3％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was taken at a relative density of 1.01 (60 ° C), then 3% times cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet air temperature of 95 ° C. Spray dry and collect dry paste powder.
实施例9Example 9
取浓缩后的广藿香浸膏，相对密度为1.11(60℃)，然后加入3％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was taken at a relative density of 1.11 (60 ° C), then 3% times cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
实施例10Example 10
取浓缩后的广藿香浸膏，相对密度为1.05(60℃)，然后加入1.5％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。The concentrated patchouli extract was taken at a relative density of 1.05 (60 ° C), then 1.5% beta-cyclodextrin was added, mixed, filtered, and subjected to an inlet air temperature of 175 ° C and an outlet temperature of 95 ° C. Spray dry and collect dry paste powder.
实施例11Example 11
取浓缩后的广藿香浸膏，相对密度为1.05(60℃)，然后加入6％倍他环糊精，混匀，滤过，在进风温度175℃，出风温度95℃条件下进行喷雾干燥，收集干膏粉。Take the concentrated patchouli extract, the relative density is 1.05 (60 ° C), then add 6% times cyclodextrin, mix, filter, at the inlet air temperature of 175 ° C, the outlet temperature of 95 ° C Spray dry and collect dry paste powder.
喷雾干燥情况及干膏收率考察结果Spray drying condition and dry cream yield inspection results
表1Table 1
实施例Example 喷雾干燥情况Spray drying 干膏收率(％)Dry paste yield (%)
11 粘塔，干膏粉流动性差Sticky tower, dry paste powder has poor fluidity 65.4065.40
22 略粘塔，干膏粉流动性一般Slightly sticky tower, dry paste powder is generally fluid 81.1581.15
33 不粘塔，干膏粉流动性好Non-stick tower, dry paste powder has good fluidity 95.4495.44
44 不粘塔，干膏粉流动性好Non-stick tower, dry paste powder has good fluidity 84.5784.57
55 略粘塔，干膏粉流动性一般Slightly sticky tower, dry paste powder is generally fluid 81.0981.09
66 不粘塔，干膏粉流动性好Non-stick tower, dry paste powder has good fluidity 96.5696.56
77 略粘塔，干膏粉流动性一般Slightly sticky tower, dry paste powder is generally fluid 78.0278.02
88 粘塔，干膏粉流动性差Sticky tower, dry paste powder has poor fluidity 70.6570.65
99 粘塔，干膏粉流动性差Sticky tower, dry paste powder has poor fluidity 71.1171.11
1010 粘塔，干膏粉流动性差Sticky tower, dry paste powder has poor fluidity 72.9772.97
1111 粘塔，干膏粉流动性差Sticky tower, dry paste powder has poor fluidity 71.4571.45
从考察结果可以看出，干膏粉浓缩后的相对密度与是否使用辅料倍他环糊精及使用倍他环糊精的量对喷雾干燥过程及干膏收率有很大影响，相对密度为1.05-1.08，倍他环糊精的用量在3％左右，喷雾干燥情况最好，干膏收率最高。It can be seen from the results of the investigation that the relative density of the dry paste powder after concentration and the use of the excipient beta-cyclodextrin and the amount of beta-cyclodextrin have a great influence on the spray drying process and the dry paste yield, and the relative density is 1.05-1.08, the dosage of beta-cyclodextrin is about 3%, the best spray drying, the highest dry cream yield.

Claims (7)

  1. 一种广藿香中药配方颗粒喷雾干燥方法，其特征在于，所述方法包含如下步骤：取浓缩后的广藿香浸膏，然后加入2％～5％倍他环糊精，混匀，滤过，在进风温度175℃～180℃，出风温度90℃～95℃条件下进行喷雾干燥，收集干膏粉。A method for spray drying of patchouli Chinese medicine formula particles, characterized in that the method comprises the steps of: taking a concentrated patchouli extract, then adding 2% to 5% beta cyclodextrin, mixing, filtering After that, the air is sprayed at a temperature of 175 ° C to 180 ° C and an outlet temperature of 90 ° C to 95 ° C to collect dry powder.
  2. 根据权利要求1所述的喷雾干燥方法，其中所述浓缩后的浸膏在60℃相对密度为1.02至1.10，优选为1.03至1.10。The spray drying method according to claim 1, wherein the concentrated extract has a relative density of from 1.02 to 1.10, preferably from 1.03 to 1.10 at 60 °C.
  3. 根据权利要求1或2所述的喷雾干燥方法，其中所述浓缩后的浸膏在60℃相对密度为1.05至1.08。The spray drying method according to claim 1 or 2, wherein the concentrated extract has a relative density of 1.05 to 1.08 at 60 °C.
  4. 根据权利要求1-3任一项所述的喷雾干燥方法，其中所述广藿香浸膏加入3％～4％的倍他环糊精。The spray drying method according to any one of claims 1 to 3, wherein the patchouli extract is added with 3% to 4% of betacyclodextrin.
  5. 根据权利要求4所述的喷雾干燥方法，其中所述广藿香浸膏加入3％的倍他环糊精。The spray drying method according to claim 4, wherein the patchouli extract is added with 3% beta-cyclodextrin.
  6. 根据权利要求1-5任一项所述的喷雾干燥方法，其中所述喷雾干燥中的进风温度为175℃，出风温度为95℃。The spray drying method according to any one of claims 1 to 5, wherein the inlet air temperature in the spray drying is 175 ° C, and the outlet air temperature is 95 ° C.
  7. 根据权利要求1-6任一项所述的喷雾干燥方法，其中干膏收率为78.02％～96.56％，优选为78.02％、81.09％、81.15％、84.57％、95.44％或96.56％。The spray drying method according to any one of claims 1 to 6, wherein the dry paste yield is from 78.02% to 96.56%, preferably 78.02%, 81.09%, 81.15%, 84.57%, 95.44% or 96.56%.
PCT/CN2018/114811 2018-05-07 2018-11-09 Spray-drying method for pogostemon cablin granular formulation WO2019214196A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020207034397A KR102466375B1 (en) 2018-05-07 2018-11-09 Spray drying method of Gwanggwakhyang granules
JP2021510502A JP7150142B2 (en) 2018-05-07 2018-11-09 Spray-drying method for broad-cut granules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810425303.6 2018-05-07
CN201810425303.6A CN110448593A (en) 2018-05-07 2018-05-07 A kind of Pogostemon cablin granule spray drying process

Publications (1)

Publication Number Publication Date
WO2019214196A1 true WO2019214196A1 (en) 2019-11-14

Family

ID=68467509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/114811 WO2019214196A1 (en) 2018-05-07 2018-11-09 Spray-drying method for pogostemon cablin granular formulation

Country Status (4)

Country Link
JP (1) JP7150142B2 (en)
KR (1) KR102466375B1 (en)
CN (1) CN110448593A (en)
WO (1) WO2019214196A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494458B (en) * 2020-05-18 2022-02-15 广州市香雪制药股份有限公司 Preparation method of patchouli formula granules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090131256A (en) * 2008-06-17 2009-12-28 주식회사파마펙스 Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release
CN101862458A (en) * 2010-06-21 2010-10-20 谭登平 Auxiliary material combination for improving atomizing and drying process of traditional Chinese medicine granules and application thereof
WO2011043397A1 (en) * 2009-10-09 2011-04-14 学校法人北里研究所 Anti-influenza virus agent
CN104523862A (en) * 2015-01-15 2015-04-22 广东一方制药有限公司 Highly-concentrated rheum officinale formula granules with purgation effect and preparation method thereof
CN107397787A (en) * 2017-08-25 2017-11-28 徐自升 A kind of fresh preparation technology for squeezing spray-dried granules medicine materical crude slice of Pogostemon cablin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5724306A (en) * 1980-07-16 1982-02-08 Wakunaga Yakuhin Kk Preparation of solid chinese herbal pharmaceutical
JPS615024A (en) * 1984-06-18 1986-01-10 Takeda Chem Ind Ltd Preparation of crude drug pharmaceutical
WO2015115512A1 (en) 2014-01-29 2015-08-06 独立行政法人産業技術総合研究所 Method for preparing water extract of ashwagandha leaves which has enhanced anti-cancer activity utilizing cyclodextrin, and pharmaceutical composition containing ashwagandha leaves
CN107157937A (en) * 2017-06-18 2017-09-15 徐漫 A kind of wrinkled giant hyssop is fresh to squeeze spray-dried granules medicine materical crude slice and its preparation technology

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090131256A (en) * 2008-06-17 2009-12-28 주식회사파마펙스 Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release
WO2011043397A1 (en) * 2009-10-09 2011-04-14 学校法人北里研究所 Anti-influenza virus agent
CN101862458A (en) * 2010-06-21 2010-10-20 谭登平 Auxiliary material combination for improving atomizing and drying process of traditional Chinese medicine granules and application thereof
CN104523862A (en) * 2015-01-15 2015-04-22 广东一方制药有限公司 Highly-concentrated rheum officinale formula granules with purgation effect and preparation method thereof
CN107397787A (en) * 2017-08-25 2017-11-28 徐自升 A kind of fresh preparation technology for squeezing spray-dried granules medicine materical crude slice of Pogostemon cablin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUAN XUJIANG, ET AL.: "Studies on the Quality Relationship of Herba Pogostemonis and its Prescription Granules", LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, vol. 17, no. 9, 30 September 2006 (2006-09-30) *

Also Published As

Publication number Publication date
CN110448593A (en) 2019-11-15
KR102466375B1 (en) 2022-11-10
JP2021519829A (en) 2021-08-12
KR20210005706A (en) 2021-01-14
JP7150142B2 (en) 2022-10-07

Similar Documents

Publication Publication Date Title
CN108420795B (en) Preparation method of particles for stopping bleeding and regulating menstruation
WO2012097579A1 (en) Pharmaceutical composition for treating melasma and preparation method therefor
WO2019214196A1 (en) Spray-drying method for pogostemon cablin granular formulation
CN102318713B (en) Glossy ganoderma tea and production process thereof
CN109260413A (en) A kind of capsule and preparation method thereof for treating gastritis
CN109966199A (en) A kind of promoting healing skin care compositions and preparation method thereof
CN103054916A (en) Application of freeze-dried purslane in preparation of medicine for treating eczema
CN100349596C (en) Medicinal powder for treating asthma and cough
CN106074807A (en) A kind of preparation method of rotor angle predicting
WO2017101210A1 (en) Gastritis treating traditional chinese medicine composition preparation method and preparation
WO2020119255A1 (en) Dioscorea alata formula granules and preparation method therefor
CN105770673A (en) Application of Chinese herba preparation containing folium artemisiae argyi in preparing drug for treating chronic gastritis
CN108567938B (en) Preparation method of bock greenbrier rhizome soft capsule
CN109692192A (en) The broken wall medicine materical crude slice for having effects that the preparation method of clearing heat and detoxicating, promoting blood circulation to remove blood stasis alangium broken wall medicine materical crude slice and being prepared by this method
KR101645078B1 (en) Method for Making Red Ginseng Extract Powder Having Exellent Physical Properties and Economic Efficiency
CN115919991B (en) Radix asteris cough relieving granule composition and preparation method thereof
CN108721221B (en) Preparation method of external powder auxiliary material and external powder using auxiliary material
CN107596316A (en) A kind of pinellia tuber for relieving cough patch and preparation method thereof
CN102085330A (en) Gallbladder-soothing capsules
CN106213245A (en) A kind of blood pressure lowering sootiness chicken wing
CN114931593A (en) Preparation process of cinnamon formula granule volatile oil inclusion compound
CN103134272A (en) Radix isatidis extraction drying method
CN109549962A (en) The preparation method of Siberian cocklebur grass broken wall medicine materical crude slice with antispastic and analgesic efficacy and Siberian cocklebur grass broken wall medicine materical crude slice prepared therefrom
CN105079135A (en) Traditional Chinese medicine combination used for treating cold and preparation method thereof
CN113712999A (en) Application of Zhuang medicine xue Dang dry paste powder in preparation of anti-inflammatory analgesic medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18918348

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021510502

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207034397

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 18918348

Country of ref document: EP

Kind code of ref document: A1